eFFECTOR Therapeutics announced the appointment of Barbara Klencke, M.D., Chief Medical Officer and Chief Development Officer at Sierra Oncology, to the company?s board of directors. Concurrent with Dr. Klencke?s appointment, Larry Lasky, Ph.D., has resigned from the company?s board of directors. Dr. Klencke has over 28 years of experience in oncology across strategic roles at biopharmaceutical companies and leading academic institutions. She currently serves as Chief Medical Officer and Chief Development Officer of Sierra Oncology, a late-stage biopharmaceutical company focused on delivering targeted therapies that treat rare forms of cancer. She previously served as Senior Vice President of Development at Onyx Pharmaceuticals, before and after its acquisition by Amgen, with responsibility for the development pipeline including Kyprolis (carfilzomib). Prior to her position at Onyx, she served as Group Medical Director in Product Development, Oncology, at Genentech. In this period, she led a variety of oncology programs including those for Kadcyla (ado-trastuzumab emtansine), Avastin (bevacizumab), and Tarceva (erlotinib). Prior to that, Dr. Klencke served as the Medical Director at Chiron Corporation and as an assistant professor of medicine at the University of California, San Francisco Medical Center.